Herbal Drugs in the Treatment of Psoriasis

Authors

  • Navneet Kharpe VIVA Institute of Pharmacy, Virar, Maharashtra, India
  • Dr. Sunita Ogale VIVA Institute of Pharmacy, Virar, Maharashtra, India
  • Jayshree Aate VIVA Institute of Pharmacy, Virar, Maharashtra, India

DOI:

https://doi.org/10.61280/tjpls.v10i6.153

Keywords:

Psoriasis, Pathogenesis, Herbal extract

Abstract

Psoriasis is an inflammatory skin condition characterized by scaling with inflammation, resulting in regions of thick, red skin covered in silvery scales. It can be itchy or painful. Systemic treatment, topical therapy, and phototherapy are used to treat psoriasis, but they have negative and potentially fatal side effects. Patients with psoriasis are more likely to acquire other conditions such as psoriatic arthritis, anxiety and depression, cancer, metabolic syndrome, cardiovascular disease, and Crohn's disease. Psoriasis is estimated to be around 2-3% of the general population. In Europe, the prevalence ranges from 0.1% to 3.2%, depending on the country. In Asia, the prevalence is generally lower, with estimates ranging from 0.1% to 1.5%. The study aims to highlight these plants, herbal formulations, and associated therapies to develop safer and more effective treatments for psoriasis. This review summarizes the current knowledge on herbal products used topically for psoriasis treatment, including their mechanisms of action such as inhibition of keratinocyte hyperproliferation, immune-inflammatory reaction. It also discusses the penetration of herbal products through the psoriatic skin barrier, novel drug delivery systems, and possible adverse effects of herbal therapy. Here, we provide a comprehensive review of the background of EP, assess the available clinical data on the efficacy of targeted therapies, and aim to provide a foundation for clinical decision making for this rare form of psoriasis.

Downloads

Download data is not yet available.

References

Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019 Mar 23;20(6):1475. doi: 10.3390/ijms20061475. PMID: 30909615; PMCID: PMC6471628.

Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013 Feb;133(2):377-85. doi: 10.1038/jid.2012.339. Epub 2012 Sep 27. PMID: 23014338.

Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers Med Sci. 2018 Jan;33(1):173-180. doi: 10.1007/s10103-017-2360-1. Epub 2017 Oct 24. PMID: 29067616; PMCID: PMC5756569.

Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb. 2016 Jun 14;3(1):79-82. doi: 10.14744/nci.2016.16023. PMID: 28058392; PMCID: PMC5175084.

Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017 Sep;140(3):645-653. doi: 10.1016/j.jaci.2017.07.004. PMID: 28887948; PMCID: PMC5600287.

Ahlehoff, O.; Gislason, G.H.; Charlot, M.; Jorgensen, C.H.; Lindhardsen, J.; Olesen, J.B.; Abildstrom, S.Z.; Skov, L.; Torp-Pedersen, C.; Hansen, P.R. Psoriasis is associated with clinically significant cardiovascular risk: A danish nationwide cohort study. J. Intern. Med. 2011,

Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018 Dec;55(3):379-390. doi: 10.1007/s12016-018-8702-3. PMID: 30109481; PMCID: PMC6244934.

Kanda N. Psoriasis: Pathogenesis, Comorbidities, and Therapy Updated. Int J Mol Sci. 2021 Mar 15;22(6):2979. doi: 10.3390/ijms22062979. PMID: 33804147; PMCID: PMC8000092.

Michalsen A, Eddin O, Salama A. A case series of the effects of a novel composition of a traditional natural preparation for the treatment of psoriasis. J Tradit Complement Med. 2015 Sep 19;6(4):395-398. doi: 10.1016/j.jtcme.2015.08.006. PMID: 27774425; PMCID: PMC5067857.

Gendrisch F, Haarhaus B, Krieger N, Quirin KW, Schempp CM, Wölfle U. The Effect of Herbal Medicinal Products on Psoriasis-Like Keratinocytes. Biomolecules. 2021 Mar 2;11(3):371. doi: 10.3390/biom11030371. PMID: 33801280; PMCID: PMC8000521.

Bylka W, Znajdek-Awiżeń P, Studzińska-Sroka E, Brzezińska M. Centella asiatica in cosmetology. Postepy Dermatol Alergol. 2013 Feb;30(1):46-9. doi: 10.5114/pdia.2013.33378. Epub 2013 Feb 20. PMID: 24278045; PMCID: PMC3834700.

Gendrisch F, Haarhaus B, Krieger N, Quirin KW, Schempp CM, Wölfle U. The Effect of Herbal Medicinal Products on Psoriasis-Like Keratinocytes. Biomolecules. 2021 Mar 2;11(3):371. doi: 10.3390/biom11030371. PMID: 33801280; PMCID: PMC8000521.

Ye H, Wang Y, Jenson AB, Yan J. Identification of inflammatory factor TNFα inhibitor from medicinal herbs. Exp Mol Pathol. 2016 Apr;100(2):307-11. doi: 10.1016/j.yexmp.2015.12.014. Epub 2016 Jan 9. PMID: 26778692.

Herman A, Herman AP. Topically Used Herbal Products for the Treatment of Psoriasis - Mechanism of Action, Drug Delivery, Clinical Studies. Planta Med. 2016 Nov;82(17):1447-1455. doi: 10.1055/s-0042-115177. Epub 2016 Aug 30. PMID: 27574899.

Togni S, Maramaldi G, Di Pierro F, Biondi M. A cosmeceutical formulation based on boswellic acids for the treatment of erythematous eczema and psoriasis. Clin Cosmet Investig Dermatol. 2014 Nov 11;7:321-7. doi: 10.2147/CCID.S69240. PMID: 25419153; PMCID: PMC4235203.

Togni S, Maramaldi G, Bonetta A, Giacomelli L, Di Pierro F. Clinical evaluation of safety and efficacy of Boswellia-based cream for prevention of adjuvant radiotherapy skin damage in mammary carcinoma: a randomized placebo controlled trial. Eur Rev Med Pharmacol Sci. 2015 Apr;19(8):1338-44. PMID: 25967706.

Published

10-12-2023

How to Cite

Navneet Kharpe, Dr. Sunita Ogale, and Jayshree Aate. “Herbal Drugs in the Treatment of Psoriasis”. Tropical Journal of Pharmaceutical and Life Sciences, vol. 10, no. 6, Dec. 2023, pp. 87-95, doi:10.61280/tjpls.v10i6.153.
Statistics
132 Views | Downloads

Issue

Section

Review Article